NKILA is a novel suppressor of local recurrence in women breast malignant phyllodes tumor patients via inhibition of the NF-κB pathway
Ying Mi,
Le Yan,
Haiyun Jin,
Ming Jin,
Di Zhu,
Hongyan Huang,
Kai Han,
Jibo Huang
Affiliations
Ying Mi
Department of Anesthesiology, Nanfang Hospital, Southern Medical University, NO. 1838 Canton Avenue North, Guangzhou, 510515, China
Le Yan
Department of Cosmetic Surgery, Nanfang Hospital Baiyun Branch, Southern Medical University, NO. 23 Yuanxiadi Road, Guangzhou, 510420, Guangdong, China
Haiyun Jin
Department of Gynaecology and Obstetrics, Southern Hospital TaiHe Branch, Southern Medical University, NO. 53 Taihe Middle Road, Guangzhou, 510540, Guangdong, China
Ming Jin
Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, 518110, China
Di Zhu
Department of Breast Surgery, Zhujiang Hospital, Southern Medical University, NO. 253 Industrial Road, Guangzhou, 510282, China
Hongyan Huang
Department of Breast Surgery, Zhujiang Hospital, Southern Medical University, NO. 253 Industrial Road, Guangzhou, 510282, China
Kai Han
Department of Dermatology, Nanfang Hospital, Southern Medical University, NO. 1838 Canton Avenue North, Guangzhou, 510515, China
Jibo Huang
Department of Cosmetic Surgery, Nanfang Hospital Baiyun Branch, Southern Medical University, NO. 23 Yuanxiadi Road, Guangzhou, 510420, Guangdong, China; Corresponding author.
The aim of the present study was to explore the functional mechanism of NF-Kappa B-interacting Long non-protein coding RNA (NKILA) in breast malignant phyllodes tumors (BMPTs). The expression and functional role of NKILA were investigated by performing qRT‒PCR, Transwell assays, and CCK‒8 assays in primary BMPT cells. A Kaplan‒Meier curve was used to assess overall survival (OS) and local recurrence-free survival (LRFS). The location and expression levels of NKILA and P65 were determined by fluorescence in situ hybridization (FISH) and immunofluorescence (IF), respectively. NKILA was downregulated in patients with BMPT, especially in patients with local recurrence. NKILA had an antitumor effect and promoted the chemosensitivity of cells to cisplatin by blocking P65 phosphorylation and nuclear translocation. In conclusion, NKILA may be a potential therapeutic target for BMPT, especially for BMPT patients with local recurrence.
